Pretomanid for tuberculosis treatment: an update for clinical purposes
Coronavirus disease (COVID-19) pandemic determined a 10 years-set back in tuberculosis (TB) control programs. Recent advances in available therapies may help recover the time lost. While Linezolid (LZD) and Bedaquiline (BDQ), previously Group D second line drugs (SLDs) for TB, have been relocated to...
Saved in:
Main Authors: | Sara Occhineri (Author), Tommaso Matucci (Author), Laura Rindi (Author), Giusy Tiseo (Author), Marco Falcone (Author), Niccolò Riccardi (Author), Giorgio Besozzi (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
by: Juliano Timm, et al.
Published: (2023) -
Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China
by: Bing Zhao, et al.
Published: (2024) -
How We Treat Drug-Susceptible Pulmonary Tuberculosis: A Practical Guide for Clinicians
by: Niccolò Riccardi, et al.
Published: (2023) -
Tuberculosis and pharmacological interactions: A narrative review
by: Niccolò Riccardi, et al.
Published: (2021) -
Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
by: Michael A. Lyons
Published: (2021)